Company intelligence / Profile preview
Faron Pharmaceuticals
- Ownership
- Public · FARN
- Employees
- ~55
- Development stage
- Phase 1
Overview
Faron’s lead asset bexmarilimab has shown positive topline results in the BEXMAB Phase II trial for high-risk MDS patients. The combination of bexmarilimab and azacitidine demonstrated a high overall response rate with good tolerability. FDA Fast Track Designation was granted for r/r MDS. Preparations are underway for a confirmatory Phase III trial as first-line therapy in HR MDS. Traumakine’s ARDS program was deprioritized after the HIBISCUS trial closed due to low COVID hospitalizations; it will now focus on organ protection indications.
- Therapeutic areas
- HematologyPulmonologyOncology
- Modalities
- Monoclonal antibodies (e.g., bexmarilimab, an anti-Clever‑1 antibody)Recombinant proteins/biologics (e.g., interferon beta‑1a in Traumakine)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Faron Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Faron Pharmaceuticals.